Immunocore names David Berman as Head of R&D

(Oxford, UK and Conshohocken, US, 15 January 2019) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform lives of people with serious diseases, today names David Berman as its new Head of Research and Development.

Read the full press releaseCompany website